| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
pharmaceutical giant Sanofi, has manufactured 35 tons of artemisinin#roughly equivalent to 70 million courses of treatment.
and Sanofi Pasteur. 10 september 2009: Two papers published in the New england Journal of Medicine show two new vaccines against H1n1 are likely to be effective after just one dose (paper 1,
Other blockbusters due to come off patent include Sanofi-aventis's anti-clotting drug Plavix (clopidogrel) and Eli lilly's schizophrenia drug Zyprexa (olanzapine.
and a range of other therapies, was acquired by Paris-based drug-maker Sanofi. The value of the deal for Genzyme's shareholders is contingent on the success of alemtuzumab in treating MS;
Gary Nabel, a flu-vaccine researcher and chief scientific officer at the biotechnology firm Sanofi in Cambridge, Massachusetts, agrees."
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011